

Supplementary Material

Phase 1 Study of Epcadostat in Combination With Atezolizumab for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Authors: Matthew D. Hellmann, Scott Gettinger, Laura Q. M. Chow, Michael Gordon, Mark M. Awad, Edward Cha, Xiaohua Gong, Gongfu Zhou, Chris Walker, Lance Leopold, Rebecca S. Heist

Table of Contents: Supplementary Table 1 – pg. 2

Supplementary Table 1. Epacadostat pharmacokinetics at steady state

Epacadostat Dose	n	C _{max} , μM	C _{min} , μM	T _{max} , h	AUC _{0-12h} , h•μM	CL/F, L/h
25 mg BID	3	0.211 ± 0.0749 (0.201)	0.0201 ± 0.0182 (NC)	2.0 (1.0, 2.0)	0.852 ± 0.176 (0.839)	69.2 ± 15.9 (68)
50 mg BID	4	0.446 ± 0.132 (0.430)	0.0845 ± 0.0233 (0.0823)	2.0 (1.0, 2.0)	2.20 ± 0.302 (2.18)	52.8 ± 8.18 (52.4)
75 mg BID	4	0.572 ± 0.266 (0.534)	0.0254 ± 0.0202 (NC)	2.0 (2.0, 6.0)	2.15 ± 0.679 (2.07)	85.9 ± 26.0 (82.8)
100 mg BID	4	0.794 ± 0.235 (0.771)	0.0875 ± 0.0317 (0.0834)	2.0 (1.0, 4.0)	3.50 ± 0.548 (3.46)	66.5 ± 10.8 (65.9)
200 mg BID ^a	6	1.79 ± 0.771 (1.53)	0.14 ± 0.112 (NC)	2.0 (1.0, 4.0)	7.48 ± 2.86 (6.76)	79.4 ± 61.2 (67.5)
300 mg BID	2	3.10, 3.27	0.247, 0.954	1.0, 2.0	9.50, 24.8	72.1, 27.6

AUC, area under the curve; BID, twice daily; CL/F, oral clearance; C_{max/min}, maximum/minimum concentration; NC, not calculated; PK, pharmacokinetic; T_{max}, time to maximum concentration

Values are presented as mean ± SD (geometric mean), except median (min, max) for T_{max}.

^a One patient had only 2 postdose PK concentration data points available and was thus excluded from this PK analysis.